Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. (Q45990634)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 February 2007

edit

Language	Label	Description	Also known as
English	Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.	scientific article published on 28 February 2007

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

title

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

main subject

osteoporosis

0 references

author

Dennis M Black

series ordinal

2

object named as

D M Black

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

Kristine Ensrud

series ordinal

5

object named as

K Ensrud

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

John P. Bilezikian

series ordinal

6

object named as

J Bilezikian

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

author name string

D E Sellmeyer

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

L Palermo

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

S Greenspan

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

C J Rosen

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

language of work or name

English

0 references

publication date

28 February 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

published in

Osteoporosis International

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

volume

18

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

issue

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

page(s)

973-979

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17333451

retrieved

18 December 2017

reference URL

http://europepmc.org/abstract/MED/17333451

cites work

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A method for the determination of the circulating concentration of 1,25-dihydroxyvitamin D

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17333451

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00198-007-0336-X

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/ctgkhdvh3zacrhoiiylc34fnbi

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

Dimensions Publication ID

1030085998

0 references

Fatcat ID

release_ctgkhdvh3zacrhoiiylc34fnbi

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/ctgkhdvh3zacrhoiiylc34fnbi

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

17333451

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/ctgkhdvh3zacrhoiiylc34fnbi

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

6474134

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45990634&oldid=2207511158"